Silo Pharma (NASDAQ:SILO) Upgraded to “Sell” at Wall Street Zen

Silo Pharma (NASDAQ:SILO) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Silo Pharma Stock Performance

Shares of NASDAQ:SILO opened at $0.58 on Friday. Silo Pharma has a 52 week low of $0.41 and a 52 week high of $4.50. The company has a market capitalization of $2.61 million, a PE ratio of -0.50 and a beta of 0.29. The company has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $1.08.

Silo Pharma (NASDAQ:SILO) last issued its earnings results on Friday, May 9th. The company reported ($0.23) EPS for the quarter. Silo Pharma had a negative net margin of 6,420.83% and a negative return on equity of 84.88%. The firm had revenue of $0.02 million during the quarter.

Silo Pharma Company Profile

Silo Pharma Inc operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.